Adult ADHD toolkit for family physicians

ADHD is a chronic neurodevelopmental disorder that often begins in childhood and continues through adolescence into adulthood. Although traditionally studied in children, it is now recognized as a significant health issue affecting approximately 4–5% of adults.¹

In adults, ADHD symptoms may manifest differently than in children. Hyperactivity often appears as inner restlessness rather than overt activity, and inattention may look like chronic disorganization, forgetfulness or poor time management. Because these presentations can be subtle, ADHD in adults is frequently underdiagnosed and undertreated in primary care.

_{1. Kessler RC, Adler L, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006 Apr;163(4):716-23.}

When ADHD goes unrecognized or not adequately treated, it can contribute to functional impairment across multiple areas of adult life. Compared with adults without ADHD, adults with ADHD may be more likely to experience:

ADHD in adulthood is also associated with higher rates of substance use disorders and other mental health conditions, and may be linked to increased risk of self-harm. These risks underscore the value of timely identification, shared decision-making, and comprehensive treatment that addresses both ADHD symptoms and co-occurring conditions.

At the same time, many adults with ADHD develop meaningful strengths and adaptive strategies over time. A strengths-informed approach can support engagement in care and help patients build on skills such as creativity, problem-solving, persistence, and resilience.

The symptom profile of ADHD in adults includes persistent difficulties with:

Symptoms of ADHD in adults: Download the handout

Patients often describe:

Emotional dysregulation is common, leading to mood swings, irritability and low stress tolerance.

Comorbid conditions frequently complicate the picture. Depression, anxiety, and bipolar, substance use and learning disorders may overlap with ADHD symptoms, making diagnosis more complex. The diagnostic guidelines in the American Psychiatric Association’s Diagnostic and Statistical Manual, Fifth Edition (DSM-5), aid in the diagnosis of ADHD in children and adults.² ADHD is commonly accompanied by other psychiatric and behavioral disorders, including conduct disorder, developmental conditions (e.g., dyslexia, autism), tic disorders, depression and anxiety.

_{2. American Psychiatric Association: DSM-5. Arlington, VA., American Psychiatric Association, 2013.}

The exact etiology of ADHD is unknown. It is thought to be caused by a complex combination of environmental, genetic and biological factors and may differ among individuals.³ Evidence from family, twin and adoption studies shows strong genetic contribution to ADHD.

However, not all of the risk is genetic. It is clear ADHD is also influenced by non-inherited factors and the gene-environment interaction. Studies show that having a biological relative with ADHD as well as prenatal and postnatal factors such as exposure to lead, tobacco, maternal stress during pregnancy and low birth weight or prematurity have been most consistently found as risk factors, but none are yet known to be definitively causal. Structural and functional brain imaging studies suggest brain maturation is delayed by a few years in individuals with ADHD and disrupted neural functioning in brain regions may underlie ADHD symptoms.⁴

Research does not support the popularly held views that ADHD is caused by eating too much sugar, watching too much television, parenting, or social and environmental factors such as poverty or family chaos. While many factors, including these, might worsen the symptoms of ADHD there is no evidence to conclude that they cause ADHD.

_{3. Gillig PM, Gentile JP, Atiq R. Attention-deficit hyperactivity disorder in adults. Psychiatry Board Review Manual. Hosp Physician. 2005;9(part 2):1–11.}

_{4. Friedman LA, Rapoport JL. Brain development in ADHD; Curr Opin Neurobiol. 2015;30:106-11.}

Many adults with ADHD find ways to adapt, leveraging strengths such as creativity, high energy and problem-solving skills. However, even high-functioning individuals may struggle with routine tasks such as bill paying, managing a household or sustaining relationships.

Some people with ADHD have fewer symptoms as they age, but some adults continue to have major symptoms that interfere with daily functioning. Many adults with ADHD are not aware they have it — they just know that everyday tasks can be a challenge.

Encouraging patients to develop structured routines, use planners or reminder apps and break tasks into smaller steps can help reduce daily challenges. Participation in support groups or coaching can reinforce these strategies. Clinicians should also acknowledge patients’ strengths and resilience, which can build confidence and improve treatment adherence.

Accurate diagnosis of ADHD in adults is essential for effective treatment but can be challenging given the overlap with other conditions. As a family physician, you play a key role in identifying symptoms, ruling out differential diagnoses and using validated tools to guide decision-making. This section reviews evaluation strategies, diagnostic criteria and recommended screening instruments for adult ADHD.

Assessment of ADHD in adults usually requires at least two visits. This approach allows time to explore symptoms, confirm persistence and assess for alternative explanations. The evaluation should include a thorough review of the patient’s history, corroboration of symptoms and determination of functional impairment.

ADHD can be diagnosed for the first time at any age. A patient does not have to have a diagnosis as a child to have it as adult. However, several inattentive or hyperactive-impulsive symptoms need to be present before age 12 for a formal diagnosis.

Clinicians should look for:

Using a structured approach ensures diagnostic accuracy and supports treatment planning. View the adult ADHD assessment, diagnosis and treatment approach algorithm.

According to DSM-5, an adult must present with at least five symptoms of inattention and/or hyperactivity and impulsivity for a period of six months or longer. These symptoms must occur in at least two settings (e.g., work and home) and cause measurable impairment.

Following DSM-5 criteria can help you avoid misdiagnosis and provides a consistent framework for evaluating patients.

ADHD symptoms overlap with many other conditions, including mood disorders, anxiety, bipolar disorder, sleep problems and thyroid disease. A careful differential diagnosis is essential to avoid mislabeling patients and to ensure comorbidities are addressed.⁵

By ruling out alternative explanations and recognizing overlapping conditions, clinicians can provide more effective, targeted care.

_{5. Ginsberg Y, Quintero J, Anand E, Casillas M, Upadhyaya HP. Underdiagnosis of Attention Deficit/Hyperactivity Disorder in Adult Patients: A Review of the Literature. Prim Care Companion CNS Disord. 2014;16(3).}

Validated screening tools can help identify ADHD symptoms and guide further evaluation. The Adult ADHD self-report scale (ASRS), Diagnostic interview for ADHD in adults (DIVA), and Conners’ adult ADHD rating scales (CAARS) are widely used.

Because self-reporting can be subjective, it is valuable to obtain collateral information from spouses, partners or colleagues. This helps provide a fuller picture of symptom patterns and daily functioning.

A wide range of rating scales and structured interviews are available to support diagnosis and ongoing monitoring. Tools such as the ASRS, Adult ADHD clinical diagnostic scale (ACDS), Brown attention-deficit disorder symptom assessment scale (BADDS), and DIVA can provide insight into symptom severity and impact. Quality of life assessments, including the adult ADHD quality of life scale, add further context.

Integrating these tools into primary care can enhance diagnostic accuracy and provide benchmarks for treatment response. Please note: some instruments may require licensing fees for you and/or the patient.

_{6. Brod, M., Perwien, A., Adler, L., Spencer, T., and Johnston, J. (2005). Conceptualization and Assessment of Quality of Life for Adults with Attention-Deficit/Hyperactivity Disorder. Primary Psychiatry, 12(6), 58-64.}

_{7. Clapp JD, Olsen SA, Beck JG, et al. The Driving Behavior Survey: Scale Construction and Validation. J Anxiety Disord. 2010;25(1):96–105. doi:10.1016/j.janxdis.2010.08.008}

_{8. Reilly MC, Zbrozek AS, Dukes EM. The Validity and Reproducibility of a Work Productivity and Activity Impairment Instrument. Pharmaco Economics 1993; 4(5):353-65.}

Managing ADHD in adults requires a comprehensive approach, addressing core symptoms and the broader impacts on daily functioning. Treatment plans often incorporate a combination of:

Because ADHD rarely exists in isolation, management should also account for co-occurring conditions, family context and the patient’s personal strengths and challenges. This section outlines current recommendations for pharmacological and non-pharmacological treatments.

The evidence on the long-term disease outcomes of treated versus untreated ADHD is somewhat inconsistent. Some studies in children and adults concluded that ADHD individuals left untreated had poorer long-term outcomes compared to treated individuals in several major categories, including:

However, treatment in these studies did not result in normalization. Studies found ADHD medications reduce symptoms and impairments. Still, there is limited and inconsistent evidence for long-term medication effects on improved social functioning, academic achievement, employment status and psychiatric comorbidity. Although some studies show an association between ADHD and suicidality, depression and substance use disorder, some emerging evidence suggests these co-occurrences could be due to shared familial risk factors rather than harmful effects of ADHD medications.

While not all symptoms can be resolved with a pharmaceutical treatment, about 60% of adults experience improvements in quality of life and symptom reduction in response to treatment.

It is important to manage patients’ expectations of treatment and to promote a sense of responsibility and personal agency. Comorbid conditions such as mood and anxiety disorders are also highly treatable.

The goal of treatment is to reduce the impact of ADHD symptoms on daily functioning while helping patients build coping strategies. Management is most effective when it combines behavioral approaches, psychoeducation and medication when appropriate. Patients should be encouraged to set realistic goals and take an active role in their care.

The AAFP recommendations for adult ADHD treatment include:

ADHD often coexists with other mental health or medical conditions. Depression, anxiety, bipolar disorder, hypertension and substance use are among the most common. Management should prioritize the most severe or impairing condition while addressing ADHD concurrently when appropriate.

It is possible that traumatic brain injury may have symptoms similar to ADHD. Current evidence shows that stimulants appear to improve attention after first-time administration and for short time periods in individuals with TBI.

Integrated care and close monitoring are important for balancing treatment strategies and minimizing adverse interactions between therapies.

CBT is a well-supported non-pharmacologic treatment for adults with ADHD. CBT helps patients identify and challenge unhelpful thought patterns, while also practicing strategies for organization, planning and emotional regulation. Behavioral components may include role-playing, exposure therapy and structured practice of problem-solving skills.

This therapeutic approach can be particularly effective when combined with medication, offering patients symptom relief and skill development.

CBT integrates cognitive (thought) and behavioral techniques to address how thoughts, feelings and actions are interconnected.

Cognitive component: Focuses on identifying and modifying “thinking errors” or “thought distortions” so the patient’s thoughts are more aligned with success and confidence.

Behavioral component: Involves engineering the environment to be more conducive to concentration and focus, and learning what reinforces and maintains problem and constructive behaviors so changes can be implemented to support a patient’s ability to function well. It includes training in skills to promote relaxation and quiet the mind; communication skills training and exposure therapy, which can help a patient overcome certain fears and avoidance.

Metacognitive therapy focuses on how patients think about tasks and problems rather than the specific thoughts themselves.

In ADHD, this therapy suggests stepping back from specific thoughts and instead understanding one’s own thinking style. Changing patterns or style of thinking could have a broad impact on how a patient manages their life. In this way, metacognitive therapy is distinct from CBT, which focuses more on the content of people's thoughts. The goal of metacognitive therapy in ADHD is to improve organization skills, planning and time management and resolve thinking distortions that lead to negative moods and the perception of limited options.

Although less studied than CBT, metacognitive therapy offers another useful option for adults seeking to improve executive function.

There is no research looking at exercise and adults with ADHD, but there is some research showing improvement of ADHD with exercise on children and adolescents. Physical activity contributes to overall health and may also help reduce ADHD symptoms. Exercise can improve concentration, support better sleep and reduce stress, all of which are common issues for adults with ADHD. While no clear guidelines exist on the most effective type or intensity of exercise, encouraging consistent activity is a safe, supportive recommendation.

For some patients, difficulty maintaining an exercise routine may reflect underlying organizational challenges that need to be addressed in treatment.

Currently, two classes of FDA-approved medications are used for ADHD treatment: Stimulant and non-stimulant.

Pharmacological treatment remains central to ADHD management. Stimulants such as methylphenidate and amphetamines are highly effective in reducing core symptoms.

ADHD stimulants boost levels of two neurotransmitters, or chemical messengers in the brain, known as dopamine and norepinephrine. Dopamine is thought to play a role in memory formation and the onset of addictive behaviors, while norepinephrine has been linked with arousal and attentiveness. Stimulants also affect dopamine and norepinephrine reuptake in certain parts of the brain and, as a result, increase the amount of these neurotransmitters helping messages within the brain be more effectively transmitted and received.

Non-stimulants like atomoxetine and guanfacine provide alternatives for patients who cannot tolerate stimulants or are at higher risk for misuse. Although their effects may take longer to appear, they can provide meaningful improvement in symptoms and functioning.

Close follow-up is necessary when initiating or adjusting ADHD medications. Patients should be reassessed within 30 days and monthly until symptoms stabilize. Once stable, follow-up every three to six months is appropriate. Each visit should include review of symptom control, medication adherence, side effects and functional progress.

Periodic medication holidays may help assess functioning without medication, though evidence in adults is limited. Careful documentation and monitoring for misuse are essential parts of stimulant prescribing.

Medication treatment risks usually relate to one or more of the following categories:

Stimulant and related medications are generally well tolerated. Stimulant side effects are usually mild and respond to waiting, adjustment of dose, timing or change in medication.

Stimulant products have a high potential for abuse. Stimulant products carry cardiovascular side effects, including tachycardia, palpitations, and blood pressure elevations. As a result, blood pressure should be monitored in those even with mild hypertension. Uncontrolled hypertension should be controlled prior to starting stimulant therapy. Warnings exist with stimulants regarding the potential risk of serious cardiovascular events, of sudden death with use in those with pre-existing structural cardiac abnormalities or other serious heart problems.

Additional adverse reactions with stimulants include insomnia, decreased appetite with possible weight loss, overstimulation, restlessness, dry mouth, unpleasant taste, diarrhea and constipation.

The amphetamine group is also associated with dizziness, euphoria, dyskinesia, tremor, exacerbations of motor and phonic tics and Tourette’s syndrome. Clinical evaluation and review of family history for tics and Tourette’s syndrome should precede use of stimulant medication.

All non-stimulant medications are Schedule II prescriptions subject to Drug Enforcement Agency (DEA) regulations. All stimulant medications are Pregnancy Category C except for guanfacine (Category B).

Stimulant products and atomoxetine should generally not be used in patients with serious heart problems or for whom an increase in blood pressure or heart rate would be problematic. Patients with a medical history of arrhythmia beyond occasional palpitations and patients with a family history of sudden death may need an electrocardiogram prior to initiating stimulant treatment. A regular physical exam is recommended as a part of diagnostic evaluation and prior to treatment initiation.

Periodically monitor patients for changes in heart rate and blood pressure.

Stimulant products are contraindicated for persons with the following co-existing conditions:

Universal precautions should be applied to all adult ADHD patients for whom stimulants are being considered. These include:

Assume all patients are at risk of misuse, abuse, diversion or having their medications stolen. Physicians should prescribe agents with less potential for abuse and monitor patients more intensely. Short-acting stimulant medications are more likely to be abused than those that are longer-acting.

There are currently four non-stimulants approved by the FDA to treat the symptoms of ADHD:

See FDA-approved non-stimulant medications for adult ADHD.

These medications lack the abuse potential of stimulants and are not controlled Schedule II drugs. The effects of non-stimulant medications may take longer to achieve. Some people report small changes in hyperactivity and impulse control within two weeks, but it may take four to eight weeks for these drugs to achieve maximum effectiveness.

There is no evidence from controlled trials to indicate how long a patient with ADHD should be treated with medications. Trials of off medications and “medication holidays” can be used to assess the patient's functioning without pharmacotherapy. Improvement may be sustained when the drug is either temporarily or permanently discontinued. The evidence on effectiveness and safety of these methods is lacking in adults.

It is generally not recommended to stop taking a stimulant medication “cold turkey,” or suddenly, which may cause uncomfortable withdrawal symptoms. Instead, a slow and controlled taper, or weaning-off period, under medical supervision is considered more desirable.

There is a documented withdrawal syndrome for stimulant medications. The initial phase (crash) of withdrawal syndrome occurs as the stimulant effects wear off. Symptoms may include:

The initial phase may last one to two days and then is followed by a longer period of several days to weeks of dysphoria (unpleasant or negative mood states). This can start within a few hours to several days of stopping use of the stimulant, in addition to at least two of the following symptoms:

Psychotic symptoms may emerge during the first one to two weeks, particularly if they were present during times of use.

Amphetamine withdrawal is largely psychological, but may be difficult to manage, particularly for friends and family members, due to mood swings.

An inpatient setting may be necessary if the patient has significant psychotic symptoms, in which case a referral to mental health services is appropriate.

No medication has been demonstrated to be effective in alleviating amphetamine withdrawal, but some medications may be useful with some symptoms.

Patients should drink at least two to three liters of water per day during stimulant withdrawal. Multivitamin supplements containing B group vitamins and vitamin C are recommended. Symptomatic medications should be offered as required for aches, anxiety and other symptoms

If patients are significantly distressed or agitated, presenting a danger to themselves or others, short-term use of benzodiazepines (diazepam 5 to 10mg QID PRN) and antipsychotics (olanzapine 2.5-5mg BD PRN) for control of irritability and agitation can be helpful, particularly in the inpatient setting. Care should be taken to limit access to large quantities of medications and to avoid development of benzodiazepine dependence. These medications should be prescribed for a maximum of seven to ten days.

The goal of treatment during withdrawal is supportive care and counselling.⁹

_{9. Clinical Guidelines for Withdrawal Management and Treatment of Drug Dependence in Closed Settings. Geneva: World Health Organization; 2009. 4, Withdrawal Management.}

ADHD affects adults across diverse backgrounds, and symptoms may vary by life stage, gender, or co-existing circumstances. Tailoring care to the needs of specific groups improves outcomes and supports long-term engagement in treatment. This section reviews considerations for adolescents transitioning into adult care, women, individuals with substance use or mental health conditions, those in forensic populations, and older adults.

As patients transition from pediatric to adult care, many lose continuity of treatment. They may stop medication, disengage from care or face new challenges related to independence. Physicians should directly involve young adults in decision-making, provide education about ongoing needs and help facilitate continuity of care.

Supporting these patients may involve shared-care arrangements between pediatric and adult providers as well as coordination with schools or workplaces to maintain accommodations.

In the transition from pediatric care to adult care, it is important to consider the following aspects:

For this patient group, the basic approach to care is to:

ADHD in women and girls is not well studied, despite evidence showing rates of ADHD are similar between males and females in adulthood. The higher rate of ADHD diagnoses in young boys compared with girls is partially attributed to developmental differences, different presentations of symptoms and other factors about ADHD in females that are not yet clearly understood.

Inattentive‑type ADHD is thought to be more common in girls and women than in boys and men. In females, ADHD may present as more subtle or internal problems (e.g., anxiety, inattention, inability to finish tasks, daydreaming) and fewer external problems (e.g., aggression, disruptive or challenging behavior). These presentations can delay recognition and increase the risk of poor outcomes.

Women with undiagnosed or untreated ADHD are at higher risk for:

Pregnancy and motherhood bring additional challenges for women with ADHD. In addition to timely diagnosis and medications, females with ADHD can also benefit from therapeutic interventions such as:

Pregnancy and stimulants

Stimulant medications are all considered “Category C” drugs: animal reproduction studies have shown an adverse effect on the fetus, and there are no adequate and well‑controlled studies in humans. Potential benefits may warrant use of the drug in pregnant women despite potential risks.

Evidence in humans is insufficient to confirm the safety of stimulants in pregnancy. There is a very low risk of having a baby born with birth defects after taking ADHD medicine, but more research is needed to determine the safest treatment options for managing symptoms of ADHD during pregnancy. Women should talk with their health care providers about options for managing ADHD symptoms before and during pregnancy.

Breastfeeding and stimulants

Limited information is available on breastfeeding and stimulant use. Amphetamine‑type stimulant drugs are thought to concentrate in breast milk and may cause irritability and disturbed sleep in babies. The long‑term effects of this exposure are unknown. Nursing infants exposed to stimulants should be monitored for insomnia, poor appetite, weight loss, and irritability; however, none of the existing studies have reported these complications. To minimize infant exposure to stimulants via breast milk, feeding should occur just prior to or as long as possible after the dose.

Stimulants and milk production

All stimulants increase dopamine activity. In addition to its effects as a neurotransmitter, dopamine also acts as a hormone to lower levels of prolactin. As a result, stimulants may lower prolactin levels and thereby reduce breast milk production.

Adults with ADHD have higher rates of substance use, particularly alcohol, tobacco and cannabis. Patients with a history of substance use disorder present unique treatment challenges, and stimulant medications must be prescribed with caution.

Managing stimulant use in patients with substance use concerns

Current evidence on the relationship between prescribed stimulant use and subsequent illicit drug use remains inconclusive. However, the following clinical considerations apply when treating ADHD in patients with current or past substance use:

Patient education on stimulant risks

All patients prescribed stimulant medications should be educated about the risks of misuse and diversion. This includes discussion of:

Comorbid conditions such as depression, anxiety and bipolar disorder are common and often complicate ADHD care. Treatment should start with the disorder causing the greatest impairment. For some patients, stimulant use may worsen mood cycling or insomnia, requiring careful selection and monitoring of medications.

Coordinated care with mental health specialists can support safe and effective treatment plans.

Research shows ADHD is disproportionately common in incarcerated populations, with estimates ranging from 25% to 40%. While ADHD does not cause criminal behavior, symptoms such as impulsivity and poor decision making may increase risks. Identifying and treating ADHD in forensic settings has been shown to improve rehabilitation outcomes and reduce recidivism.

Limited research exists on ADHD in adults aged 60 years and older; however, emerging studies show symptoms often persist into senior years and can be mistakenly attributed to normal aging or cognitive decline. Because symptom expression changes with age, many older adults may not meet full diagnostic criteria yet still experience significant impairment.

Motor hyperactivity in adulthood frequently shifts to “inner” hyperactivity, manifesting as restlessness, excessive fidgeting or talking, inability to relax and difficulty sitting quietly for long periods. Impulsivity may present as outbursts of anger, impatience, careless driving or making decisions without adequate forethought. Inattention in older adults may include disorganization, forgetfulness, poor performance in planning and completing tasks, frequent task shifting and time management difficulties.

Given the limited evidence base, individualized therapy and careful risk–benefit assessment should guide diagnosis and treatment for older adults with ADHD.

Primary care physicians can manage many adults with ADHD, but referral to psychiatry or behavioral health is appropriate for patients with severe dysfunction, suicidal ideation, psychosis or resistant symptoms. Collaboration with specialists also benefits patients with complex comorbidities or suspected substance use disorders.

Shared-care arrangements can support continuity of care, ensure medication safety, and help patients access a broader range of treatment resources.

Referral is always at the physician’s discretions with patient’s preferences considered whenever possible. During assessment and diagnosis process, consider referral to a psychiatrist or mental/behavioral health professionals in the following several presentations and co-conditions:

During treatment and monitoring, consider referral to a psychiatrist in the following situations:

View team-based care patient resources

Education and support are essential components of ADHD management. Many adults are unaware of the nature of their condition or the resources available to them. Providing patients with tools for self-assessment, guidance for daily living, and access to continuing resources empowers them to take an active role in their care. This section highlights key resources for patients and physicians alike.

Most adult patients with ADHD can benefit from education about ADHD, skill building trainings and adjuvant psychotherapy. A variety of self-help resources such as books, websites and apps exist for adults with ADHD. Several tips and resources for the patients are summarized in the patient handout, Managing Adult ADHD.

One option for identifying resources available within local communities is the Neighborhood Navigator, a resource offered by the AAFP and The EveryONE Project^®. The Neighborhood Navigator is an interactive tool you can use to connect patients to resources and programs in their neighborhoods. Over 40,000 social services are listed by zip code, which includes various physical health and mental health options.